How Does Voydeya Work? Mechanism of Action Explained in Plain English

Voydeya (danicopan) is described as a "complement Factor D inhibitor" — a phrase that might sound complicated if you're not familiar with how the immune system works. But the concept behind how Voydeya works is actually quite elegant once it's broken down. This article explains the mechanism of action of Voydeya in plain English, without requiring a medical degree.

First: Understanding the Complement System

Your immune system has many different components. One of them is the complement system — a collection of proteins that work together to identify and destroy threats like bacteria, viruses, and abnormal cells. Think of it as an automatic alarm and response system that activates when threats are detected.

The complement system has three activation pathways — classical, lectin, and alternative. The alternative pathway is the one relevant to Voydeya. It is constantly active at a low level, checking for threats, and normally kept under control by protective proteins on healthy cells. In PNH, those protective proteins are missing from blood cells — leaving them vulnerable to attack by the complement system.

The Problem in PNH: Missing Complement Protection

In PNH, a mutation in the PIGA gene causes red blood cells to be produced without complement-regulatory proteins (CD55 and CD59). Without these proteins:

The complement system cannot distinguish these red blood cells from threats

The alternative pathway attacks and destroys them — both inside blood vessels (intravascular hemolysis, or IVH) and outside blood vessels (extravascular hemolysis, or EVH)

The destruction of red blood cells causes anemia, fatigue, and other serious complications

How C5 Inhibitors Work (and Why They're Not Enough for Some Patients)

Most PNH patients are treated with C5 inhibitors — eculizumab (Soliris) or ravulizumab (Ultomiris). These drugs block a protein called C5, which is near the end of the complement cascade. Blocking C5 prevents the formation of the Membrane Attack Complex (MAC), which is responsible for IVH (destroying red blood cells inside blood vessels).

The problem is that C5 inhibitors do NOT stop the earlier part of the pathway — including the step where C3 protein coats (opsonizes) red blood cells. C3-coated red blood cells are then removed and destroyed by the spleen and liver — this is EVH. For 10–20% of PNH patients, this C3-mediated EVH causes ongoing anemia even when their C5 inhibitor is working perfectly for IVH.

Where Voydeya (Danicopan) Fits In: Blocking Factor D

Voydeya works upstream — earlier in the complement cascade than C5 inhibitors. Specifically, danicopan is a reversible inhibitor of complement Factor D.

Here's the step-by-step of how it works:

Factor D is required to make the alternative pathway's enzyme (C3 convertase). Factor D does this by cleaving Factor B into pieces called Ba and Bb.

The Bb fragment is needed to form C3 convertase. C3 convertase then cleaves C3 into C3b, which coats red blood cells (opsonization) — marking them for destruction by the spleen and liver.

Danicopan binds to Factor D and blocks its activity. Without active Factor D, Factor B cannot be cleaved, C3 convertase cannot form, and C3b cannot coat red blood cells. The entire amplification loop of the alternative pathway is interrupted.

Result: EVH is prevented. Red blood cells are no longer opsonized by C3b and are protected from extravascular destruction in the spleen and liver.

Why Is Voydeya Combined with a C5 Inhibitor?

Voydeya specifically addresses the alternative pathway and EVH — but it does not replace the C5 inhibitor's role in blocking IVH (intravascular hemolysis through the MAC). The combination of a C5 inhibitor + Voydeya provides more complete coverage:

C5 inhibitor (eculizumab/ravulizumab): Blocks MAC → prevents IVH

Voydeya (danicopan): Blocks Factor D → prevents C3b opsonization → prevents EVH

Together, the combination targets both the upstream alternative pathway amplification (EVH) and the downstream terminal pathway (IVH). This explains why Voydeya is never used as monotherapy — without C5 inhibition, the IVH component would remain uncontrolled.

Voydeya in Plain Terms: A Summary

Think of the complement system like a series of dominoes. In PNH, the dominoes fall onto your red blood cells. C5 inhibitors stop the dominoes near the end. Voydeya stops the dominoes much earlier in the sequence — at Factor D — so the chain reaction that leads to EVH never begins.

For more information, see our companion article What Is Voydeya? Uses, Dosage, and What You Need to Know. For help with specialty pharmacy access, visit medfinder.com.